February 7, 2023 Bio/Pharma/CRO Roche announces positive data from global phase III programme for crovalimab in PNH, a rare life-threatening blood condition Read more
February 2, 2023 Uncategorized [Ad hoc announcement pursuant to Art. 53 LR] Changes in Roche’s Corporate Executive Committee Read more
February 2, 2023 Acad, Gov/Utilities [Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results for 2022 despite decline in demand for COVID-19 products Read more
February 1, 2023 Uncategorized European Commission approves label expansion of Roche’s Hemlibra to include people with moderate haemophilia A in the EU Read more
January 26, 2023 Life Science Tools Product Launch Roche launches COVID-19 PCR test to detect the fast spreading XBB.1.5 Omicron sub-variant Read more
January 19, 2023 Bio/Pharma/CRO [Ad hoc announcement pursuant to Art. 53 LR] Roche’s Tecentriq plus Avastin is the first treatment combination to reduce the risk of cancer returning in people with certain types of early-stage liver cancer in a Phase III trial Read more
January 12, 2023 Uncategorized Roche announces the European Commission approval of Xofluza for the treatment and prevention of influenza in children aged one year and above Read more
January 6, 2023 Acad, Gov/Utilities FDA grants priority review to Roche’s bispecific antibody glofitamab for people with relapsed or refractory large B-cell lymphoma Read more
December 23, 2022 Acad, Gov/Utilities FDA approves Roche’s Lunsumio, a first-in-class bispecific antibody, to treat people with relapsed or refractory follicular lymphoma Read more
December 21, 2022 Acad, Gov/Utilities Clinical Research/Diagn. Microscopy FDA approves Roche’s Actemra for the treatment of COVID-19 in hospitalised adults Read more
